Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd (NY: BHVN )

45.59 +0.40 (+0.89%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd

< Previous 1 2 3 4 5 6 7 8 Next >
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
The FDA's advisors recently backed Pfizer's Covid shot for young children. 
Via Investor's Business Daily
Hopeful Golden Cross Forms On Biohaven Pharma Hldgs's Chart
If history is any guide, there may be good fortune ahead for shares of Biohaven Pharma Hldgs (NYSE:BHVN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish... 
Via Benzinga
Looking Into Biohaven Pharmaceutical's Return On Capital Employed
According to data from Benzinga Pro, during Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $318.85 million. Despite a 41.43% increase in earnings, the company posted a loss of $116.90... 
Via Benzinga
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
The company is planning to soon ask for FDA approval of etrasimod in ulcerative colitis. 
Via Investor's Business Daily
Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study
Via Benzinga
Recap: Biohaven Pharma Hldgs Q1 Earnings
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement. 
Via Benzinga
BIOHAVEN INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN
From Kahn Swick & Foti, LLC
Via Business Wire
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review
Elon Musk put his Twitter deal "on hold" but says he's "still committed" to it. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Upgrades 
Via Benzinga
Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?
BHVN stock is enjoying a nearly 70% jump today after Biohaven Pharmaceutical announced it has been acquired by Pfizer. 
Via InvestorPlace
Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; Crude Oil Down 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. 
Via Benzinga
103 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Reverses Morning Rally as Recession Fears Swirl
Stocks are shedding their premarket gains at midday, and are now looking to extend yesterday's major selloff. 
Via Talk Markets
Mid-Day Market Update: U.S. Stocks Turn Lower; Biohaven Pharmaceutical Shares Jump
U.S. stocks turned mostly lower midway through trading, with the Dow Jones dropping more than 100 points on Tuesday. 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'
One analyst says the deal "couldn't have come at a better time." Here's why. 
Via Investor's Business Daily
Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know
Via Benzinga
BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Pfizer to Acquire Biohaven Pharmaceuticals
From Pfizer Inc.
Via Business Wire
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine
European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who... 
Via Benzinga
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
From Pfizer Inc.
Via Business Wire
Axsome Therapeutics' Good Fortune Reverses As Its Migraine Drug Hits A Hurdle
Last week, Axsome stock soared on its depression drug. This week is a different story. 
Via Investor's Business Daily
AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship
Flagship Pioneering is swiping one of AbbVie's biggest names. 
Via Investor's Business Daily
Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90
On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.